- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 2,104
matching trials from the live ClinicalTrials.gov search.
- Conditions
- End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
- Interventions
- Ferric Citrate
- Drug
- Lead sponsor
- Winthrop University Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Hesperidin and Calcilock, Hesperidin, Control
- Dietary Supplement
- Lead sponsor
- Purdue University
- Other
- Eligibility
- Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Colorectal Carcinoma, Ulcerative Colitis
- Interventions
- Atorvastatin Calcium, Biopsy of Colon, Biospecimen Collection, Placebo Administration, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Kansas City, Kansas
- Conditions
- Leukemia
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, thioguanine, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Palo Alto, California • Sacramento, California + 43 more
- Conditions
- Shock, Septic
- Interventions
- Lactated Ringer, Normal Saline, Plasma-lyte
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Months to 17 Years
- Enrollment
- 9,041 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 22
- States / cities
- Davis, California • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Lymphoma
- Interventions
- Fludarabine, Novantrone, Decadron, Rituximab, Interferon, Doxorubicin, Vincristine, Bleomycin, Cyclophosphamide, Etoposide, Cisplatin, Ara-C, Methyl-Prednisolone, Procarbazine, Prednisone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 76 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimetrexate glucuronate, Leucovorin calcium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 21
- States / cities
- Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 15 more
- Conditions
- Hypercalcemia, Familial Primary Hyperparathyroidism
- Interventions
- Parathyroid hormone testing, Serum calcium testing
- Procedure
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Venous Ulcer, Infection
- Interventions
- Restore Calcium Alginate Dressing, AquaCel Ag Wound Dressing
- Device
- Lead sponsor
- Hollister Wound Care LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- St. Petersburg, Florida • Shreveport, Louisiana • Holmdel, New Jersey + 2 more
- Conditions
- Leukemia, Lymphoma, Sarcoma
- Interventions
- leucovorin calcium, trimetrexate glucuronate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Marginal Zone Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Marginal Zone Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- pharmacological study, rituximab, dexamethasone, laboratory biomarker analysis
- Other · Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Coronary Artery Disease
- Interventions
- Percutaneous Coronary Intervention
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Glendale, California • Hartford, Connecticut + 30 more
- Conditions
- Hyperuricosuria, Kidney Stones
- Interventions
- Febuxostat, Allopurinol, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 25 more
- Conditions
- Ulcerative Colitis, Ileal Pouch
- Interventions
- Aquamin, Placebo
- Drug
- Lead sponsor
- Muhammad N Aslam, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- mezigdomide, Pomalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 810 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 56
- States / cities
- Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Interventions
- oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 9
- States / cities
- Fairfield, Connecticut • Guilford, Connecticut • Hartford, Connecticut + 6 more
- Conditions
- Drugs, Non-Prescription, Medication Systems
- Interventions
- Verbal advice, Prescription
- Behavioral
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 19 Years to 50 Years · Female only
- Enrollment
- 246 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Osteoporosis
- Interventions
- Low Calcium Diet, High Calcium Diet
- Dietary Supplement
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 12 Years to 15 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Breast Neoplasms, Breast Cancer, Cancer of the Breast
- Interventions
- Docetaxel with Cytoxan, Dexamethasone
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Atherosclerosis
- Interventions
- Rosuvastatin 10 mg, Darapladib 160 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 20 Years to 64 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
- Interventions
- Zemplar® injection, Hectorol® injection
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Bellevue, Nebraska • Omaha, Nebraska
- Conditions
- Hypoparathyroidism, DiGeorge Syndrome
- Interventions
- PTH 1-34
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Coronary Artery Disease
- Interventions
- standard of care lipid therapy, Aggressive lipid therapy
- Drug
- Lead sponsor
- Annapoorna Kini
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York